When are scientific advances translated into commercial products via startup formation? Although prior literature has offered several categories of answers, the commercial potential of a scientific advance is generally unobserved and potentially confounding. We assemble a sample of over 20,000 "twin" scientific discoveries in order to hold constant differences in the nature of the scientific advance, thereby allowing us to more precisely examine characteristics that predict startup commercialization. We find that teams of academic scientists whose former collaborators include "star" serial entrepreneurs are much more likely to commercialize their own discoveries via startups, as are more interdisciplinary teams of scientists.
Introduction
The technologies underlying some of the most successful companies in the world-including Google's PageRank search algorithm, E-Ink's "electronic paper", Mobileye's autonomous driving technology, RSA's cryptography algorithm, and Genentech's recombinant growth hormone-were discovered by academic scientists at universities who then commercialized them via startup formation. In 2017, the U.S.
Association of University Technology Managers (AUTM) reported that over 1,000 startups were created from university intellectual property. Given increasing interest in academic technology commercialization (Sanberg, et al. 2014 ), we ask: what factors explain which scientific advances are translated into commercial products via startup formation?
New ventures as vehicles for commercializing academic technologies are important for at least three reasons. First, young firms are disproportionately involved in job growth (Haltiwanger, Jarmin & Miranda, 2013) . Second, new ventures commercializing academic advances tend to co-locate near pioneering academic staff, thus contributing to regional economic development (Zucker, Darby & Brewer, 1998) . Third, engaging the original scientists for on-going development may be critical to realizing the full potential of embryonic technologies (Jensen & Thursby, 2001) .
Two prior literatures provide candidate answers to a general form of our research question. One stream highlights the role of entrepreneurial opportunity recognition, which in turn may be influenced by individual experience and the occupational or training environment in which the scientist is embedded. A second stream instead stresses financial and knowledge resource munificence in the institutional or local entrepreneurial ecosystem. One common factor clouding inference in the typical study across these two streams of work, however, is the difficulty of controlling for differences at the technological discovery level. Academic discoveries, in particular, can have varied "latent" commercial potential which can be difficult to discern (unknown even to the participants, much less to us as researchers).
Our empirical design builds on the Bikard & Marx (2018) method of assembling "twin" scientific discoveries. We scale up this effort considerably and study the likelihood that only one of two articles reporting the same scientific discovery is commercialized via a startup. Doing so helps to hold constant technological differences, enabling us to examine the empirical salience of two novel team-based variables within the entrepreneurial opportunity-based literature in predicting startup commercialization: 1) prior "star" commercialization peer effects and 2) more interdisciplinary collaborators.
Related literature
As noted, a key challenge that both the entrepreneurial opportunity recognition and entrepreneurial ecosystem literatures grapple with is the suitability of different scientific advances and technologies to be translated into commercial applications. 1 For example, Azoulay, Ding & Stuart (2007) address the related research question of "who patents?" among academic scientists. They conclude that patenting is a function of scientific opportunities (patenting is often observed after a flurry of scientific publications); furthermore, these same authors construct a measure of "latent commercializability," which predicts faculty patenting.
The measure is based on keywords in scientists' publications which overlap with words which had previously been used in patent applications. Closer to the setting of commercialization via new venture formation, Shane (2001) finds differences in patent characteristics (such as measured "importance" and "scope") correlate with university technologies which are the subject of startup formation. 2 A more fundamental problem is that the literature on academic commercialization frequently characterizes academy-originated technologies as "embryonic" (Jensen & Thursby, 2001) , which compounds the difficulty of ascertaining and measuring latent commercializability. The inference issue therefore becomes more than one simply of measurement. Instead, if participants and decision-makers themselves are uncertain of the latent commercializability of a given technology, the problem of unobservability looms much larger. Even holding a given technology constant, there can be dramatic differences in entrepreneurial opportunity recognition (and hence commercialization attempts). As an example, Shane (2000) analyzes the case of eight sets of entrepreneurs recognizing different opportunities in response to a single invention, Three-D Printing™. His results illustrate that entrepreneurship reflects differences in information about opportunities, and that individual differences influence commercialization paths. In our context, differences among scientists who come up with "twin" discoveries may help to explain variation in entrepreneurial outcomes.
Not only can individual differences impact entrepreneurial opportunity recognition, several studies also stress the important role of peer influence. Nanda & Sorenson (2010) find a positive relationship 1 The entrepreneurial ecosystem literature explaining commercialization analyzes the role of the resource environment, particularly venture capital. The outcome of interest is typically centered on economic activity (venture starts, employment growth, etc.) at the regional level, with measures of venture capital activity as a regressor (e.g., Stuart & Sorenson, 2003; Samila & Sorenson, 2011) . Latent commercializability is also an issue in this literature; however, due to the differing levels of analysis (regional economic outcomes versus individual scientific discoveries), it is difficult to directly compare results from this literature with ours. between exposure to peers in the workplace with entrepreneurial experience and the likelihood of venture founding. In an empirical setting closer to ours, Stuart & Ding (2006) similarly find that academic life scientists who engage in commercial science (via firm founding or joining a scientific advisory board) have more coauthors with a commercial orientation. These studies all interpret peer effects as a social means of information transmission, which in turn impact the likelihood of startup-based commercialization.
We build on this peer-effects channel, shifting the unit of the analysis from an individual worker to the scientific discovery. This change is essential given our research question but more fundamentally because most discoveries are produced by teams of scientists (Wuchty, Jones, & Uzzi, 2007) . Specifically, we propose that scientists' prior affiliation with "star commercializers"those in the extreme right tail of commercial activity, will likely have a positive impact on entrepreneurial commercialization attempts, holding the scientific discovery constant. This is because such exposure is likely to be highly salientas in the case of MIT professor Robert Langer, who has helped spawn over 40 startups and has been awarded over 1,000 patents (Krass, 2018) .
We also investigate the influence of scientific-team composition on commercialization outcomes.
A growing literature on team composition and performance suggests that more interdisciplinary teams can outperform (under certain circumstances) those of higher ability (Hong & Page, 2004) . Leahy, Beckman, & Stanko (2017) find that even though interdisciplinary research is more difficult to publish, it garners more attention. In the context of entrepreneurial commercialization, we expect more interdisciplinary teams are more likely to collectively recognize commercial applications, holding constant the technical advance.
Empirical approach
As discussed above, a primary challenge in assessing when academic researchers commercialize their discoveries via startups is heterogeneity among discoveries. The ideal experiment to assess when academic researchers commercialize their discoveries via startups would involve random matching of researchers and discoveries, which is of course impractical. Instead, we take advantage of the fact that different researcher teams sometimes make the same or very similar discoveries-which we label "twins". Bikard & Marx (2018) analyze 316 twin discoveries drawn from articles in the top 15 scientific journals during 2000-2010, which are primarily from the life sciences. We apply a similar technique to all published papers in the Web of Science from 1955-2017. We begin by finding all pairs of papers that a) were published no more than a year apart, b) are cited at least five times, c) share 50% of forward citations, and d) are both cited by at least one other paper. Applying these criteria to the Web of Science yields a list of 40,392 papers from 20,196 potential twin discoveries. The next step is to determine whether the potential twin discoveries are cited adjacently (i.e., within the same parenthesis). Adjacent citations suggest that forward-citing researchers are unable to attribute the discovery to a single paper, with the listed references within the citation parentheses receiving co-attribution.
Accounting for latent commercializability via "twin" discoveries
Identifying adjacent citations involves inspecting the text of more than 1.2M papers that jointly cite what may be twin discoveries (although reference lists are available electronically, adjacent citation listings are not). Retrieving all such papers is impractical, as many if not most published articles reside behind paywalls and are inaccessible at scale. However, PDFs of many papers are freely available-sometimes in draft form-and have been indexed by Google Scholar (GS). Although GS does not support bulk downloads, over a period of 19 months we retrieved approximately 280,000 publicly-available, non-paywalled PDFs corresponding to the 1.2M papers that jointly cited our 40,392 potential twin discoveries. For 29,257 of the 40,392 potential twin discoveries, we were able to determine whether they were adjacently cited by the PDFs that cited both of them. Of those, we found that 23,853 papers were cited adjacently. These comprise our population of twin discoveries, which should have similar latent commercializability among twins.
Appendix A provides more detail on the twin discoveries, which hail from more than 3,000 academic institutions in 106 countries and span more than 200 scientific fields.
Outcome variable: entrepreneurial commercialization of scientific discoveries
Our dependent variable indicates whether academic researchers commercialize their scientific discoveries via a startup. To our knowledge, a large sample of academic scientific discoveries commercialized via startups has not been previously assembled. To be sure, many studies of technology transfer have tracked out-licensing or other forms of commercializing discoveries (Friedman & Silberman, 2003) . Zucker, Darby, & Brewer (1998) examine the correlation between the presence of prominent scientists and entrepreneurial activity at the state level, but no direct connection between the scientist and startup is measured. Studies of academics-turned-entrepreneurs (Stuart & Ding, 2006) note when an academic either founded or advised a life-sciences startup but do not directly trace that involvement back to a particular discovery. In any case, prior studies have not considered the entire team of scientists involved with a particular discovery.
We measure entrepreneurial commercialization in two ways. First, we detect entrepreneurial commercialization via the U.S. Small Business Innovation Research (SBIR) grants. The SBIR program is targeted at encouraging "domestic small businesses to engage in federal research and research & development that has the potential for commercialization" and has awarded non-dilutive funding in excess of $45B since the program was initiated in 1982 (www.sbir.gov/about). We interpret pursuing SBIR funds as an indicator of commercialization aspirations. We calculate the pairwise overlap between scientists on a focal article and either the primary contact or principal investigator of SBIR awards two years before the publication of the article and up until five years thereafter. Scientists and SBIR personnel are compared individually, with an overall match score computed according to a) whether the surname is an exact vs. fuzzy match b) frequency of the surname in the Web of Science c) whether the middle initial matches (more details are provided in Appendix A). A weighted average of author/awardee overlap is computed to yield an overall article/SBIR match score. If multiple SBIR awards have identical author-overlap scores, we break ties with temporal proximity.
Our second method of determining entrepreneurial commercialization involves finding patentpaper pairs (Murray, 2002) where the patent is assigned to an entrepreneurial venture. The premise is that while scientific publications are the typical currency of academia, patents and their associated legal protection are valued much more in the commercial domain, and specifically by venture capitalists (Hsu & Ziedonis, 2013) . Our algorithmic effort is therefore aimed at identifying patents which are granted to entrepreneurial ventures which cover the same or similar scientific advance in which there is overlap in authors. We start by finding the subset of twin academic discoveries that are cited by patents and check for overlap between the authors of the paper and the inventors named on the patent, following a process similar to that with papers and SBIR awardees. In some cases, the authors of an article have an identical overlap score with more than one patent. Ties are broken in two steps. First, the patent-paper pair closest in time (i.e., publication year vs. patent application year) is retained as in Thompson, Ziedonis, & Mowery, (2018) .
If two patents in the same year form pairs with the same paper, we further resolve ambiguity following (Magerman, et al. 2015) by choosing the patent-paper pair with the highest cosine similarity between the abstract of the article and the summary text of the patent. (Cosine similarity is computed using Term Frequency * Inverse Document Frequency, where all Web of Science abstracts and patent summaries are used as the corpus.) However, not every patent-paper pair represents entrepreneurial commercialization. The scientists may merely patent the discovery but assign it to the university. Alternatively, one or more scientists on a paper may cooperate with an established firm to commercialize the discovery. We thus subset the list of patent-paper-pairs to those that are assigned to entrepreneurial ventures, as determined from VentureSource and CrunchBase. We find 139 academic articles that were commercialized via patent-paper pairs assigned to startups and 89 that were commercialized via SBIR awards, for a total of 228 entrepreneurial commercialization events. More details regarding construction of the outcome variable are in Appendix B.
Appendix Table B1 also provides validation of the measure, confirming in a stratified random sample that both both patent-paper-pairs and overlapping SBIR grants truly reflect instances of a startup commercializing an academic discovery with the involvement of one of the original scientists.
Covariates
Given that our measure of entrepreneurial commercialization depends on an algorithm that scores the number of name matches (weighted for quality), twin discoveries with more authors might mechanically have higher overlap scores. Thus we control for the number of scientists on each article corresponding to the twin discovery. In addition to controlling for the number of scientists, we also enter covariates for the nature of the scientific team. First, we include the combined number of years the scientists on a focal paper have been research-active.
Second, we include a measure of the interdisciplinarity of the scientific team. This measure is calculated as one minus the Herfindahl-Hirsch index of the subjects for articles written by scientists on the focal paper. If all articles by all scientists on the focal article published all of their papers in the same subject, this variable would be set to zero.
Third, we measure whether the previous collaborators of the scientists on the paper include a "star" serial entrepreneurial commercializer. This variable is reminiscent of Stuart & Ding's (2016) measure of the number of prior collaborators who served as founders or advisory-board members of startups that filed for a IPO. Our measure differs in several ways. First, we measure involvement with early-stage ventures and not just those that complete an IPO. Second, instead of summing all instances of entrepreneurial involvement, we focus on "star" serial entrepreneurs who lie at the 99 th percentile of entrepreneuriallycommercializing academic scientists in the year of the scientist's most recent collaboration. Third, instead of focusing on individual scientists we check whether any scientist on the paper had previously collaborated with such a star. Additional characteristics of 'star' commercializers are available in Appendix C.
Although the twin discoveries should have similar latent commercial potential, as found by Bikard & Marx (2018) , individual articles may report the same discovery in more clinical or industry-relevant ways. We control for such factors by including the count of forward citations (in the next five years) to the focal article from patents assigned to corporations, as these may indicate that a particular article reporting the scientific discovery appear to have more commercial value than its twin. Patent-to-paper citations are computed following Fleming et al. (2018) .
As noted earlier, entrepreneurial activity may depend on geography. We include a lagged count of venture investments in the same postal code as the focal discovery. We also include a lagged count of SBIR awards in the same postal code, which is by definition zero outside the U.S. Organizational characteristics may also influence commercializability. We control for the corresponding author's institutional research productivity in the same field as the paper. 3 Table 1 contains descriptive statistics and correlations. Table 2 shows difference-of-means tests between twin discoveries that were entrepreneurially commercialized vs. not. Discoveries that were commercialized by startups have more scientists on the team and more experienced scientists, and more interdisciplinary scientific teams. Commercialized discoveries have about 40% more citations from industry patents and, interestingly, are from institutions with somewhat fewer publications in the subject of the focal paper.
Descriptive statistics and estimation
Perhaps the most dramatic univariate difference is in the share of discoveries that have a 'star' commercializer among the scientists' prior collaborators. Barely one percent of non-commercialized discoveries have ties to such a star, compared with more than 10% of commercialized discoveries.
Commercialized discoveries are moreover located in postal codes with more venture capital investments and SBIR awards.
[ Tables 1 and 2 about here] Following practice in epidemiological twin studies (Carlin et al., 2005) , we estimate the likelihood of entrepreneurial commercialization using fixed effects for papers that report a twin discovery. The regression equation is:
where j represents the twin discovery and i represents a paper reporting the twin discovery.
captures whether the focal article was commercialized by a startup. captures whether the scientists on a given article had previously collaborated with a "star" entrepreneurial commercializer. reports the interdisciplinarity of the scientific team. is a vector of other covariates. Finally, is a fixed effect for the twin discovery.
Our primary estimation approach utilizes linear probability models (LPM). Following Beck (2015), we also estimate conditional logit models, which exclude any duplicate discovery whether neither (or both) of the twin discoveries is commercialized. In robustness checks (Appendix D), we also estimate LPM models restricted to those twins where one article was commercialized and the other was not.
Results
We begin in Table 3 by evaluating the relationship between entrepreneurial commercialization and various groups of covariates. In column (1), it is evident that papers with larger teams of scientists are more likely to be commercialized via startups. This is expected, as our measure relies on name overlap between scientists and either patent inventors or SBIR recipients. Column (2) shows only an imprecise relationship between the institution's research productivity in the same field as the paper. Column (3) fails to precisely estimate the relationship between citations from patents assigned to corporations, which is reassuring as one might be concerned that our dependent variable could be conflated with articles simply being cited more often by patents.
[ Table 3 about here] Columns (4) and (5) add the key explanatory variables. Column (4) shows that discoveries where the scientific team is more interdisciplinary are more likely to be commercialized by startups. Column (5) shows that discoveries where the scientists' prior collaborators include a "star" commercializer are more likely to be commercialized via startups. Finally, column (6) examines the relationship between entrepreneurial commercialization and two geographic measures of the commercialization environment.
We do not see a relationship between our dependent variable and either the previous-year count of venturecapital investments or the count of SBIR awards in the same postal code.
All of the foregoing covariates are included in column (7), which maintains statistical significance on the interdisciplinarity of the scientists as well as past collaboration with a 'star' commercializer. Using estimated coefficients from column (7) to calculate magnitudes, a one-standard-deviation increase in authorship team interdisciplinarity (0.27) corresponds to a 2.2% increase in the likelihood that a duplicate discovery will be commercialized by a startup. The presence of a "star" commercializer among the scientists' past collaborators is associated with a 7.5% increase. Robustness tests, including conditional logit estimation, are available in Appendix D.
Figure 1 gives additional insight into the relationship between our key explanatory variables. Panel
A shows the predictive marginal effect of having a 'star' commercializer, estimated from column (7) of where one was commercialized and the other is not.) The trendline shows that more interdisciplinary teams of scientists are more likely to commercialize their discoveries via a startup.
[ Figure 1 about here]
In Table 4 , we dig deeper into the nature of interdisciplinarity and 'stars.' Column (1) repeats column (7) of Table 4 to facilitate comparison. In columns (2-4) we explore how interdisciplinarity is involved with the entrepreneurial commercialization of science. Our primary measure captures the overall interdisciplinarity of the work conducted by the scientists on a focal paper, but this could be driven by several subfactors. In column (2), we replace the interdisciplinarity variable with a simple count of the primary disciplines represented by the scientists on the paper. (By "primary" discipline we mean the discipline in which each author publishes most often.) The positive, statistically-significant estimate of the associated coefficient suggests that having scientists from a variety of disciplines is important, not just having a set of scientists from the same discipline who also work relatively often in other areas.
[ Table 4 about here]
That said, it does not appear crucial-or even advantageous-in the commercialization process for scientists to fully specialize. The covariate in column (3) of Table 4 counts the number of scientists who publish exclusively in a single field. If specialists were critical to the commercialization process, we might expect this coefficient to be precisely estimated, but it is not. Nor is it the case that it suffices to have one highly interdisciplinary scientist collaborating with a set of relative specialists. In column (4), we calculate each scientist's individual level of interdisciplinarity and then enter as a covariate the difference between the most interdisciplinary scientist and the mean of the team. The negative coefficient suggests that such a configuration does not facilitate commercialization. In other words, a set of relative specialists relying on a single boundary-spanner are less likely to commercialize than a set of scientists in a variety of disciplines who themselves are not overly specialized.
The remaining columns of Table 4 verify that it is the presence of a "star" commercializer among the scientists' past collaborators that explains the patterns in Table 3 and not simply an association with a highly prolific or highly-cited researcher. We test this alternative hypothesis in two ways. In column (5), we replace the 'star' commercializer variable-again, being in the 99 th percentile-with an indicator for having a past collaborator whose count of publications was in the 99 th percentile in the year of that most recent collaboration. Column (6) repeats this exercise with an indicator for whether any of those past collaborators was in the 99 th percentile of citations per article (in a five-year window following publication).
Neither of these coefficients is estimated with much precision. We conclude that not just a star researcher but a star commercializer is necessary to facilitate entrepreneurial commercialization of science.
Discussion
By building a method to measure academic entrepreneurial commercialization attempts at scale and embedding the analysis in an empirical design to hold constant a given scientific advance, we investigate two team-based correlates of scientific-commercial translation. We find evidence that a team of more interdisciplinary scientists, as well as past collaboration with 'star' commercializers, predict the commercialization of academic scientific discoveries via startups.
A limitation of our methodology is that we may not capture scientific commercialization by a startup that licenses or otherwise appropriates the discovery without involvement from the original scientists. Given the prior literature about the importance of engaging the inventor and aligning incentives for commercialization success (e.g., Jensen & Thursby, 2001) , we hope to spur more research in the academic startup channel of technology commercialization.
From a team design perspective, our results suggest that well-rounded individuals who are part of teams who are themselves well-rounded are more likely to pursue startup commercialization (a specific form of building team interdisciplinarity). While it remains to be seen whether this a general phenomenon beyond academia and the possible mechanisms underpinning the relationship, we hope future research explores this and related issues in greater detail.
Similarly, prior commercialization star affiliation holds a number of implications for attracting and retaining exceptional commercializers in organizations and institutions, and suggests a specific form of spillover to such relationships.
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T. Stuart, O. Sorenson (2003) . "Liquidity events and the geographic distribution of entrepreneurial activity," Administrative Science Quarterly, 48 (2) Table 3 OLS estimates for startup-commercialization of 23,851 twin discoveries Note: fixed effects for each duplicate discovery and robust standard errors: *=p<.1; **=p<.05; ***=p<.01.
(1) (2) (3) (4) (5) (6)
# authors 0.000888** 0.000743* (0.000413) (0.000412) Ln paper authors' cumulative experience 0.000319 -0.000199 (0.000843) (0.00103) Ln institution # papers on topic -0.00128 -0.00396* (0.00179) (0.00208) Ln 5-yr citations from industry patents 0.00631 0.00696 (0.0112) (0.0111) Interdisciplinarity of scientists' output 0.00967** 0.00839** (0.00398) (0.00424) Scientists' prior coauthors include 'star' commercializer 0.0756*** 0.0746*** (0.0242) (0.0242) Ln same-postalcode # investments (CB) 0.000767 0.000418 (0.00288) (0.00285) Annual ln SBIR awards in postalcode 0.00423 0.00473 (0.00289) (0.00290) Constant 0.00333 0.0108*** 0.00890*** 0.00491** 0.00867*** 0.00875*** 0.00350 (0.00280) (0.00199) (0.00107) (0.00194) (0.000659) (0.000759) (0.00352) R-squared 0.509 0.509 0.509 0.509 0.512 0.509 0.513
Table 4: Deeper examination of interdisciplinarity and prior collaboration with 'star' commercializers
Note: All models estimated w/OLS; fixed effects for each duplicate discovery; robust standard errors: *=p<.1; **=p<.05; ***=p<.01.
(1) (2) (3) (4) (5)
# authors 0.000703* 0.000461 0.000576 0.000518 0.000881** 0.000838** (0.000408) (0.000405) (0.000777) (0.000426) (0.000414) (0.000412) Ln paper authors' cumulative experience -0.000295 -0.000334 0.000671 7.76e-05 0.000411 -0.000144 (0.00102) (0.00100) (0.00107) (0.00100) (0.00105) (0.00111) Ln institution # papers on topic -0.00419** -0.00294 -0.00394* -0.00418** -0.00290 -0.00337 (0.00208) (0.00211) (0.00207) (0.00208) (0.00209) (0.00208) Ln 5-yr citations from industry patents 0.00735 0.00735 0.00729 0.00738 0.00611 0.00617 (0.0110) (0.0110) (0.0110) (0.0110) (0.0112) (0.0112) Ln same-postalcode # investments (CB) 0.000422 0.000403 0.000419 0.000444 0.000740 0.000732 (0.00284) (0.00285) (0.00285) (0.00284) (0.00288) (0.00288) Annual ln SBIR awards in postalcode 0.00474 0.00485* 0.00479* 0.00477* 0.00450 0.00447 (0.00289) (0.00290) (0.00289) (0.00289) (0.00290) (0.00290) Interdisciplinarity of scientists' output 0.00839** 0.00895** 0.00854** (0.00423) (0.00426) (0.00425) # scientists' primary disciplines represented 0.00368** (0.00151) # scientists who publish only in one subject 0.000173 (0.000844) Difference in max & mean scientist interdisciplinarity -0.0123* (0.00659) Scientists' prior collaborators includes 'star' commercializer 0.0930*** 0.0928*** 0.0932*** 0.0934*** (0.0256) (0.0256) (0.0256) (0.0256) Scientists' prior collaborators includes one in 99th percentile productivity -0.00285 (0.00249) Scientists' prior collaborators includes one in 99th percentile of cites per article 0.00107 (0.00231) Constant 0.00394 0.00170 0.00608* 0.0168** 0.00178 0.00247 (0.00348) (0.00396) (0.00328) (0.00694) (0.00356) (0.00353) R-squared 0.514 0.514 0.514 0.514 0.510 0.510
Figure 1: Interdisciplinarity, "stars", and commercialization of academic science by startups
Panel A: Predictive marginal effects of the scientists on a given discovery having had a 'star' commercializer among their past coauthors. Marginal effects are calculated from column (7) of Table 3 .
Panel B: Binned scatterplot of the likelihood that a given scientific discovery was commercialized by a startup. 20 bins are calculated for the 436 twin papers where one was commercialized and the other was not. All controls from column (7) of Table 3 are included.
Appendix A: Characteristics of Twin Discoveries
Our 23,851 twin discoveries range from 1973-2015 and are from more than 3,000 academic institutions in 106 countries. Figure A1 shows their temporal distribution. (There may be additional twin discoveries in the distant past, but these are hard to discover because SBIR data are available only since 1983, and patentto-paper citations are difficult to collect pre-1976 given errors in OCR processing of patent applications.) Table A1 shows the distribution of twin discoveries by geography, discipline, and institution. Over half of twin discoveries occur in the U.S., followed by Great Britain, Germany, and Japan. When considering pairs of twin papers, one-third of pairs both occur in the U.S. and 37% of twin papers are in the same country.
Figure A1: Temporal Distribution of Twin Discoveries
Panel B details the disciplinary fields of the twin discoveries. The life sciences are responsible for many of the most popular categories of twin discoveries, although Physics is the most popular category. Astronomy & Astrophysics is also a frequent source of twin discoveries. Finally, Panel C tabulates the academic institutions with the most twin discoveries. While each agency administers its own individual program, awards are made on a competitive basis following proposal evaluation. There are three phases to the SBIR program: Phase I is to "establish technical merit, feasibility, and commercial potential…" and such awards "normally do not exceed $150,000 total costs for 6 months." Phase II awards are to: "…continue the R/R&D efforts initiated in Phase I…Only Phase I awardees are eligible for a Phase II award…[and] normally do not exceed $1M total costs for 2 years." Phase III is for small businesses to pursue commercialization objectives, though the SBIR program does not fund Phase III development.
We implement name matching for Web of Science authors vs. SBIR personnel, removing hyphenation and other punctuation. (We examine the first 30 authors on each paper although some papers have more than 30 authors.) Although full names are available for SBIR and patents, many papers only have the authors' surname and initial(s). If both the author and the SBIR awardee have both initials present but these do not match, a score of zero is assigned. Names lacking first initials are ignored. Otherwise, a match score is assigned through a series of steps. First, we determine whether the surnames match exactly or nearly, where "nearly" indicates that both surnames are more than five characters long and fewer than ¼ of the characters must be changed to convert one to the other (i.e., Levenshtein distance). Moreover, the surnames must start with the same letter (e.g., "Rogers" and "Bogers" are not matched). Two names are treated as a preliminary match if the surname meets these criteria and the first initials also match. We want to avoid the situation where the author "J Smith" is assumed to the be same as the SBIR awardee "Jesse Smith", so we score surnames according to their inverse frequency of appearance in the Web of Science. For instance, surname Smith would be downscaled to near-zero as it is among the most common author names. Surnames that comprise less than 0.007% of all authors (i.e., 2 nd percentile) are not downscaled. If only two authors match between the paper and SBIR grant, and both of them represent more than 0.005% of all authors, we conclude that there is no match. Regardless of surname, matches are considered exact if both first and second initials are present for both names and they both match. A similar algorithm is implemented for computing overlap between authors of articles and inventors on patents.
Finally, in identifying unique authors we initially relied on the Web of Science author ID. However, in our testing we found that many scientists with different surnames were grouped under a single ID. We split author IDs based on different surnames or, if surnames matched, different first and (if available) middle initials. Doing so raised the number of authors in the Web of Science from approximately 1 million to about 73 million.
To evaluate whether our algorithm truly captures instances of startup commercialization, we examine a small random sample of both types of potential examples of commercialization to seek direct confirmation of our algorithmic approach. Panel A of Table B1 shows the examples of paper-patent pairs, and Panel B shows the examples of SBIR grants. We start by randomly selecting five scientific papers drawn from each route of identifying commercialization. For each of these papers, we retrieve the underlying scientific article via Google Scholar searches and record the authors. For Panel A, we retrieve the associated patent from our algorithmic approach described in the main text via Google Patents (patents.google.com). We record the patent title, inventors, and assignee. For Panel B, we retrieve the associated SBIR grants to the focal companies via sbir.gov and record the grant title, funding agency and amount, and the listed principal investigator/business contact. To verify the linkages in both panels between scientific paper and commercialization activity, we conduct web searches in the following manner: we find the overlapping names between paper author and patent inventor (Panel A) or SBIR contact (Panel B)those are shown in bold in the table. We search the web for the union of the overlapped name(s) and the new venture entity (patent assignee in Panel A; SBIR company in Panel B). The final column in both panels of the table provide web links (all accessed in January 2019) providing confirmation of commercialization activity in all ten instances.
One interesting case is the second entry in Panel A. We initially had difficulty finding confirmation, but then found that one of the author/inventors, Larry Gold, had founded a company, NeXagen to commercialize his technology, changed the name of the company, and subsequently sold that company to Gilead Sciences. The patent was subsequently reassigned to Gilead Sciences, which is why initially we thought we had failed to find a linkage.
[Appendix Table B1 
